Literature DB >> 4039454

Interactions of cis-platinum with cellular zinc and copper in rat liver and kidney tissues.

R P Sharma.   

Abstract

In the present study the effects of cis-diamminedichloroplatinum II (cis-DDP) on tissue and subcellular concentrations of endogenous Zn and Cu was investigated in liver and kidneys of rats injected i.p. with 5 mg/kg of cis-DDP. The binding of Pt to cytosolic ligands and its effect on Zn and Cu binding was also investigated. cis-DDP significantly reduced cellular Zn (20%) and Cu (23%) levels particularly in the kidneys. Intracellularly, these decreases were largely reflected in the corresponding cytosolic fractions, with 64% decrease in Zn and 56% in Cu concentrations. At 24 h following cis-DDP injection, in both liver and kidneys, about 50% of cytosolic Pt was present as low molecular weight (LMW) species and the remainder as protein-bound. A small proportion of cellular Pt was bound to a metallothionein-like protein in the liver as well as the kidneys. The binding of renal Zn to cytosolic proteins and LMW Zn-binding ligands was significantly decreased by cis-DDP. In the liver cytosol, there was a marked redistribution of Zn and Cu from LMW Zn/Cu-binding ligand to the MT-like proteins.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4039454     DOI: 10.1016/0031-6989(85)90065-7

Source DB:  PubMed          Journal:  Pharmacol Res Commun        ISSN: 0031-6989


  9 in total

1.  Zinc acetate pretreatment ameliorates cisplatin-induced Sertoli cell dysfunction in Sprague-Dawley rats.

Authors:  L M Pogach; Y Lee; W Giglio; M Naumoff; H F Huang
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Protection by ebselen against cisplatin-induced nephrotoxicity: antioxidant system.

Authors:  K Husain; C Morris; C Whitworth; G L Trammell; L P Rybak; S M Somani
Journal:  Mol Cell Biochem       Date:  1998-01       Impact factor: 3.396

3.  Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells.

Authors:  P A Andrews; M P Murphy; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Experimental basis for increasing the therapeutic index of cis-diamminedicarboxylatocyclobutaneplatinum(II) in brain tumor therapy by a high-zinc diet.

Authors:  F Doz; M E Berens; C F Deschepper; D V Dougherty; V Bigornia; M Barker; M L Rosenblum
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 5.  Metallothionein and anticancer agents: the role of metallothionein in cancer chemotherapy.

Authors:  F Doz; N Roosen; M L Rosenblum
Journal:  J Neurooncol       Date:  1993-08       Impact factor: 4.130

6.  Cisplatin induced nephrotoxicity and the modulating effect of glutathione ester.

Authors:  E Babu; V K Gopalakrishnan; I N Sriganth; R Gopalakrishnan; D Sakthisekaran
Journal:  Mol Cell Biochem       Date:  1995-03-09       Impact factor: 3.396

7.  Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury.

Authors:  Alaa N A Fahmi; George S G Shehatou; Abdelhadi M Shebl; Hatem A Salem
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-23       Impact factor: 3.000

8.  Azadirachta indica attenuates cisplatin-induced neurotoxicity in rats.

Authors:  Ahmed Esmat Abdel Moneim
Journal:  Indian J Pharmacol       Date:  2014 May-Jun       Impact factor: 1.200

Review 9.  Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences

Authors:  Mehdi Nematbakhsh; Zahra Pezeshki; Fatemeh Eshraghi Jazi; Bahar Mazaheri; Maryam Moeini; Tahereh Safari; Fariba Azarkish; Fatemeh Moslemi; Maryam Maleki; Alireza Rezaei; Shadan Saberi; Aghdas Dehghani; Maryam Malek; Azam Mansouri; Marzieh Ghasemi; Farzaneh Zeinali; Zohreh Zamani; Mitra Navidi; Sima Jilanchi; Soheyla Shirdavani; Farzaneh Ashrafi
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.